(Total Views: 509)
Posted On: 07/13/2025 2:16:37 PM
Post# of 155721
Quote:
This is why MARAVIROC
Was sidelined. Everyone thought this new entry inhibitor when it came out almost 20 years ago was going to be a game changer and it was temporarily until HIV replicating on an order of trillions of new copies very quickly was able to switch phenotypes and enter through CXCR4. Those patients who had been achieving viral load suppression With MVC later developed what appeared to be mutation and that allowed HIV to enter cells through another doorway called CXCR four instead of CCR five making those patients no longer able to take MVC.
If I remember correctly maraviroc had a very low number of patients move over to CXCR4. With 84% receptor occupancy it's not as effective as leronlimab, but like leronlimab it bolsters the immune system to help kill the virus besides blocking its entry into CD4 cells. Killing off the virus heavily reduces the chance of a tropism switch to CXCR4. Maraviroc was relegated to the dustheap by better combination ART therapies and possible liver damage.
(9)
(0)
